About
Andrew Sinclair joined Abingworth in 2008 after working as an equity analyst in the pharmaceutical and biotechnology sectors. He heads the firm's Publics and Late Stage strategies, works across CCD and private investing, and evaluates public company opportunities including VIPE investments. Before Abingworth he was a Senior Equity Analyst and Director at HSBC Global Markets covering mid-cap pharmaceuticals, and previously worked at Credit Suisse and SG Cowen. He holds a PhD in Chemistry and Genetic Engineering from the BBSRC Institute of Plant Science, Norwich, and a BSc in Microbiology from King's College London, and qualified as a chartered accountant with KPMG.
Contact· self-published, not guessed
Invests in
Biotech
Experience
- AbingworthPartner, Portfolio Managercurrent2008 — present
Skills & more
From Andrew's professional profile.
Deals · 1
Verona PharmaBoard seat
via Abingworth · filed Jul 2020 · $200.2M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
Adicet BioAscendcAMPfieldEntact BioHilleVaxPhathomR1 TherapeuticsSolenoTimberlyne
Sources: the firm's website · SEC Form D filings.
Colleagues at Abingworth
Network5
Investors connected to Andrew in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Andrew Sinclair?
- Andrew Sinclair joined Abingworth in 2008 after working as an equity analyst in the pharmaceutical and biotechnology sectors. He heads the firm's Publics and Late Stage strategies, works across CCD and private investing, and evaluates public company opportunities including VIPE investments. Before Abingworth he was a Senior Equity Analyst and Director at HSBC Global Markets covering mid-cap pharmaceuticals, and previously worked at Credit Suisse and SG Cowen. He holds a PhD in Chemistry and Genetic Engineering from the BBSRC Institute of Plant Science, Norwich, and a BSc in Microbiology from King's College London, and qualified as a chartered accountant with KPMG.
- Where does Andrew Sinclair work?
- Andrew Sinclair is Partner at Abingworth.
- What does Andrew Sinclair invest in?
- Andrew Sinclair invests in Biotech.
- What check size does Andrew Sinclair write?
- Andrew Sinclair typically writes checks of $15M – $30M.
- What boards does Andrew Sinclair sit on?
- Andrew Sinclair holds tracked board seats at Adicet Bio, Ascend, cAMPfield, Entact Bio, HilleVax, Phathom, R1 Therapeutics, Soleno, Timberlyne, Verona Pharma.